metastasizing pleomorphic adenoma: a fascinating enigma

Clicks: 141
ID: 230566
2012
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #185 of 309 articles by views in Frontiers in pharmacology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 309 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Among salivary gland neoplasms, metastasizing pleomorphic adenoma (MPA) constitutes an extremely rare group of tumors. The present paper reports a case of pleomorphic adenoma (PA) in submandibular gland that, after more than 30 years of initial treatment, recurred and metastasized to ipsilateral neck lymph nodes and parotid gland. In an attempt to elucidate the malignant behavior of metastasizing pleomorphic adenoma, we performed Ki-67, p53, p16, and bcl-2 immunohistochemistry staining of our case sample. Many immunohistochemistry staining studies have been done on malignant salivary gland tumors. However, to the best of our knowledge no immunohistochemistry staining of the aforementioned markers has been previously performed on metastasizing pleomorphic adenoma.
Reference Key
santaliz-ruiz2012casemetastasizing Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Luis E. IV Santaliz-Ruiz;Gary Morales;Héctor Santini;María Sánchez-Santiago;Axel Arroyo
Journal Frontiers in pharmacology
Year 2012
DOI
10.1155/2012/148103
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.